

Pershina E.S. <sup>1,2</sup>, Shilova A.S. <sup>1</sup>, Nesterov A.P. <sup>1</sup>, Solovieva V.A. <sup>1</sup>, Tuul D.M. <sup>1</sup>, Shchekochikhin D.Yu. <sup>1,2</sup>, Gilyarova E. M. <sup>1</sup>, Kovalev K. V. <sup>1</sup>, Magomedova Z. M. <sup>1,2</sup>, Meshkov V. V. <sup>1</sup>, Romashkina E. R. <sup>2</sup>, Pakhomov P. V. <sup>3</sup>, Ognerubov D. V. <sup>4</sup>, Khairullin I. I. <sup>1</sup>, Sinitsyn V. E. <sup>5</sup>

## CLINICAL AND ECONOMIC EFFECTIVENESS OF CT ANGIOGRAPHY METHODS IN THE EMERGENCY DEPARTMENT FOR INTERMEDIATE-RISK PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME

## SUPPLEMENTARY MATERIALS

Table 1. Indications and contraindications for CTA in the emergency department

Indications for CTA	Suspected NSTE-ACS in patients at medium risk of AMI (GRACE score 109-140 and/or HEART 4-6)		
Indications for triple rule-out protocol	Difficulties in differential diagnosis between ACS, PE, and AAS Based on clinical, investigational, and laboratory data (physical examination, ECG, echocardiogram, troponin, D-dimer) and PE and AAS probability scores (Wells, Geneva, ADviSED		
Contraindications for CTA	<ol> <li>Known allergy to an iodinated contrast agent</li> <li>Glomerular filtration rate (GFR) &lt; 30 mL/min/1.73m<sup>2</sup></li> <li>For CTA: known history of myocardial infarction, stenting of coronary arteries, coronary artery bypass grafting (CABG).</li> <li>Severe calcification of coronary arteries</li> </ol>		

CTA, computed tomography angiography, which includes CT coronary angiography and the triple rule-out protocol; NSTE-ACS, non-ST-segment elevation acute coronary syndrome, AMI, acute myocardial infarction; PE, pulmonary embolism; AAS, acute arterial syndrome.

Table 2. Number of all patients diagnosed with NSTE-ACS in the specified period (69 days)

## Number of medium-risk patients diagnosed with NSTE-ACS

	Number of medium-risk patients diagnosed with No.12-res				
Parameter	Absolute value	Relative value (of all medium-risk patients)	Relative value (of all patients)		
CTA performed (medium risk), total	37	34%	14.3%		
ACS was not confirmed by CTA	27	25%	10.0%		
ACS was confirmed by CTA	7	6.4%	2.7%		

NSTE-ACS, non-ST-segment elevation acute coronary syndrome,

CTA, computed tomography angiography (CT coronary angiography and triple rule-out protocol).

<sup>&</sup>lt;sup>1</sup> Pirogov Municipal Clinical Hospital #1, Moscow, Russia

<sup>&</sup>lt;sup>2</sup> Sechenov First Moscow State Medical University, Moscow, Russia

<sup>&</sup>lt;sup>3</sup> National Medical Research Center of Otolaryngology, Moscow, Russia

<sup>&</sup>lt;sup>4</sup> Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia

<sup>&</sup>lt;sup>5</sup> Lomonosov Moscow State University, Moscow, Russia



Table 3. Economic costs associated with the utilization of CTA techniques for medium-risk patients with NSTE-ACS

Types of costs	Cost of treatment per patient, rubles	Number of patients in this cohort	Cost of treatment of all patients, rubles			
Costs of examinations of patients in whom NSTE-ACS was ruled out when using a protocol including CTA in appropriate cases						
Costs for treatment of all medium-risk patients with unconfirmed NSTE-ACS using CTA	17,000 (diagnostic therapeutic MES including CTA)	27	459,000 (17,000 × 27)			
Costs for treatment of all medium-risk patients with unconfirmed NSTE-ACS for whom CTA was not utilized	20,429 (ICU stay until transfer to the department) + 55,921 (mean cost of cardiac MES in the department)	61	4,657,350 (20,429 + 55,921) × 61			
Estimated treatment costs for all patients with unconfirmed NSTE-ACS in the analyzed period	-	-	459,000 + 4,657,350 = 5,116,350			
Estimated treatment costs for all patients with unconfirmed NSTE-ACS per year*	-	-	27,064,750			
Costs of examination of patients in whom NSTE-ACS was ruled out using the protocol with hospitalization for further evaluation in all cases (standard approach, without CTA)						
Costs for treatment of all medium-risk patients with unconfirmed NSTE-ACS in the analyzed period	20,429 (ICU stay) + 55,921 mean cost of cardiac MES in the department)	27 + 61 = 88	6,718,800 (20,429 + 55,921) × 88			
Estimated treatment costs for all patients with unconfirmed NSTE-ACS per year*	-	-	35,541,478			

<sup>\*</sup> Recalculation per year using the proportional method. NSTE-ACS, non-ST-segment elevation acute coronary syndrome, CTA, computed tomography angiography; ICU, intensive care unit; MES, medical and economic standard.